Japan-Flag  Korea-Flag  China-Simplified-Flag  China-Traditional-Flag 

Conference Menu

Overview
Register
Day 1
Day 2
Short Course
View Brochure
Attendee List
Posters
Hotel & Travel
Exhibitor Kit
View Exhibitors/Floor Plan
Exhibit Contract
Sponsor & Exhibits
Podcasts
Press Pass 
Request Brochure
Archives 


Premier Sponsor:

OpenEye_Vertical

Corporate Sponsor:
 

Schrodinger logo
 

Corporate Support Sponsor:

sysmex 

Media Sponsor:

Bio-IT-Word

Sponsoring Society:

ISCB

Lead Sponsoring Publications:

Clinical Informatics News

Gen

Insight Pharma Reports

nature

PharmaVoice

Science AAAS 

Scientific Computing Logo Small

The Scientist

Web Partners:

FierceBiotech

Fierce Biotech IT

FiercePharma

GenomeWeb 


PodcastNew Podcast! 

 

Structures, Chemical Probes, New Biology, New Targets for Drug Discovery: Is This the Right Sequence? 
with Chas Bountra, Ph.D., Professor, Translational Medicine; Head, Structural Genomics Consortium, University of Oxford
 

CHI recently spoke with Dr. Chas Bountra, Head of the Structural Genomics Consortium (SGC), and Professor of Translational Medicine and an Associate Head of Medical Sciences at the University of Oxford. In this podcast, Dr. Bountra discusses how the SGC is impacting drug discovery and their work on developing novel probes, specifically for epigenetic targets. Dr. Bountra also gives a sneak peek into his keynote lecture joining the Structure-Based Drug Design and Chemical Biology for Target Validation meetings, May 22 in Boston.

Download Podcast  



PodcastNew Podcast! 

 

Using Structure and Property-Based Methods to Create a Quality ITK Inhibitor 
with Jason Burch, Ph.D., Scientist, Medicinal Chemistry, Genentech
 

At the upcoming Structure-Based Drug Design conference in Boston, Dr. Jason Burch, a Medicinal Chemist at Genentech will give a talk on structure-based design and property optimization of potent and selective pyrazole carboxamide interleukin-2 inducible t-cell kinase (itk) inhibitors for the treatment of inflammatory diseases. CHI recently spoke with Dr. Burch about why he chose to pursue ITK inhibitors, important considerations for developing these types of inhibitors, and what techniques were used to improve pharmaceutical properties of the lead matter. Dr. Burch also discusses how advances in genomics and demand for personalized treatments has changed drug design techniques.

Download Podcast